Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer

Authors: Yuji Yamashita, Shin Nishiumi, Seishi Kono, Shintaro Takao, Takeshi Azuma, Masaru Yoshida

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Triple-negative breast cancer (TN) is more aggressive than other subtypes of breast cancer and has a lower survival rate. Furthermore, detailed biological information about the disease is lacking. This study investigated characteristics of metabolic pathways in TN.

Methods

We performed the metabolome analysis of 74 breast cancer tissues and the corresponding normal breast tissues using LC/MS. Furthermore, we classified the breast cancer tissues into ER-positive, PgR-positive, HER2-negative breast cancer (EP+H-) and TN, and then the differences in their metabolic pathways were investigated. The RT-PCR and immunostaining were carried out to examine the expression of ELOVL1, 2, 3, 4, 5, 6, and 7.

Results

We identified 142 of hydrophilic metabolites and 278 of hydrophobic lipid metabolites in breast tissues. We found the differences between breast cancer and normal breast tissues in choline metabolism, glutamine metabolism, lipid metabolism, and so on. Most characteristic of comparison between EP+H- and TN were differences in fatty acid metabolism was which were related to the elongation of very long chain fatty acids were detected between TN and EP+H-. Real-time RT-PCR showed that the mRNA expression levels of ELOVL1, 5, and 6 were significantly upregulated by 8.5-, 4.6- and 7.0-fold, respectively, in the TN tumors compared with their levels in the corresponding normal breast tissue samples. Similarly, the mRNA expression levels of ELOVL1, 5, and 6 were also significantly higher in the EP+H- tissues than in the corresponding normal breast tissues (by 4.9-, 3.4-, and 2.1-fold, respectively). The mRNA expression level of ELOVL6 was 2.6-fold higher in the TN tumors than in the EP+H- tumors. During immunostaining, the TN and EP+H- tumors demonstrated stronger ELOVL1 and 6 staining than the corresponding normal breast tissues, but ELOVL5 was not stained strongly in the TN or EP+H- tumors. Furthermore, the TN tumors exhibited stronger ELOVL1 and 6 staining than the EP+H- tumors.

Conclusions

Marked differences in fatty acid metabolism pathways, including those related to ELOVL1 and 6, were detected between TN and EP+H-, and it was suggested that ELOVL1 and 6-related fatty acid metabolism pathways may be targets for therapies against TN.
Appendix
Available only for authorised users
Literature
1.
The Global Burden of Cancer 2013. JAMA Oncol. 2015;1:505–27.
2.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–502.CrossRefPubMed
3.
Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res. 2011;17:952–8.CrossRefPubMedPubMedCentral
4.
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.CrossRefPubMed
5.
6.
Junichi K. Treatment strategies against triple negative breast cancer. Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery. 2012;29:293–7.
7.
Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. 2015;6:26560–74.CrossRefPubMedPubMedCentral
8.
9.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.CrossRefPubMed
10.
Muñoz-Pinedo C, El Mjiyad N, Ricci J-E. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3:248.CrossRef
11.
12.
13.
German JB, Watkins SM, Fay L-B. Metabolomics in practice: emerging knowledge to guide future dietetic advice toward individualized health. J Am Diet Assoc. 2005;105:1425–32.CrossRefPubMed
14.
German JB, Bauman DE, Burrin DG, Failla ML, Freake HC, King JC, et al. Metabolomics in the opening decade of the 21st century: building the roads to individualized health. J Nutr. 2004;134:2729–32.PubMed
15.
Suzuki M, Nishiumi S, Kobayashi T, Azuma T, Yoshida M. LC-MS/MS-based metabolome analysis detected changes in the metabolic profiles of small and large intestinal adenomatous polyps in ApcMin/+ mice. Metabolomics. 2016;12:68.CrossRef
16.
Mashego MR, Rumbold K, De Mey M, Vandamme E, Soetaert W, Heijnen JJ. Microbial metabolomics: past, present and future methodologies. Biotechnol Lett. 2007;29:1–16.CrossRefPubMed
17.
18.
Wishart DS. Metabolomics: applications to food science and nutrition research. Trends Food Sci Technol. 2008;19:482–93.CrossRef
19.
Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu R-H, et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. Breast Cancer Res. 2014;16:434.CrossRefPubMedPubMedCentral
20.
Guo S, Wang Y, Zhou D, Li Z. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci Rep. 2014;4:5959.CrossRefPubMedPubMedCentral
21.
Budczies J, Pfitzner BM, Györffy B, Winzer KJ, Radke C, Dietel M, et al. Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer. 2015;136:1619–28.CrossRefPubMed
22.
23.
Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjøsne H, Giskeødegård GF, et al. Metabolic characterization of triple negative breast cancer. BMC Cancer. 2014;14:941.CrossRefPubMedPubMedCentral
24.
Budczies J, Brockmöller SF, Müller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteome. 2013;94:279–88.CrossRef
25.
Brauer HA, Makowski L, Hoadley KA, Casbas-Hernandez P, Lang LJ, Erick RP, et al. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res. 2013;19:571–85.CrossRefPubMed
26.
Cajka T, Fiehn O. Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry. Trends Analyt Chem. 2014;61:192–206.CrossRefPubMedPubMedCentral
27.
Moestue SA, Dam CG, Gorad SS, Kristian A, Bofin A, Mælandsmo GM, et al. Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res. 2013;15:R16.CrossRefPubMedPubMedCentral
28.
Sakai A, Suzuki M, Kobayashi T, Nishiumi S, Yamanaka K, Hirata Y, et al. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Biomark Med. 2016;10:577–86.CrossRefPubMed
29.
Leonard AE, Pereira SL, Sprecher H, Huang Y-S. Elongation of long-chain fatty acids. Prog Lipid Res. 2004;43:36–54.CrossRefPubMed
30.
Chang CC, Zhang C, Zhang Q, Sahin O, Wang H, Xu J, et al. Upregulation of lactate dehydrogenase a by 14–3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. 2016;23:35270–83.CrossRef
31.
Clem BF, Clem AL, Yalcin A, Goswami U, Arumugam S, Telang S, et al. A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling. Oncogene. 2011;30:3370–80.CrossRefPubMedPubMedCentral
32.
Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res. 2004;43:266–81.CrossRefPubMed
33.
Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, et al. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene. 2010;29:139–49.CrossRefPubMed
34.
Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002;62:1966–70.PubMed
35.
Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer. 2007;120:1721–30.CrossRefPubMed
36.
Ramírez de Molina A, Gutiérrez R, Ramos MA, Silva JM, Silva J, Bonilla F, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene. 2002;21:4317–22.CrossRefPubMed
37.
Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004;64:4270–6.CrossRefPubMed
38.
Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res. 2011;71:3236–45.CrossRefPubMed
39.
Muir K, Hazim A, He Y, Peyressatre M, Kim D-Y, Song X, et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 2013;73:4722–31.CrossRefPubMed
40.
Marien E, Meister M, Muley T, Gomez Del Pulgar T, Derua R, Spraggins JM, et al. Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget. 2016;7:12582–97.CrossRefPubMedPubMedCentral
41.
Feng Y-H, Chen W-Y, Kuo Y-H, Tung C-L, Tsao C-J, Shiau A-L, et al. Elovl6 is a poor prognostic predictor in breast cancer. Oncol Lett. 2016;12:207–12.PubMedPubMedCentral
42.
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–44.CrossRefPubMed
43.
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer - deciphering the heterogeneity. Clin Cancer Res. 2014;20:782–90.CrossRefPubMedPubMedCentral
44.
Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res. 2007;105:319–26.CrossRef
45.
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. 2015:e31–9.
Metadata
Title
Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer
Authors
Yuji Yamashita
Shin Nishiumi
Seishi Kono
Shintaro Takao
Takeshi Azuma
Masaru Yoshida
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3554-4

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway

Technical advance

Intravital imaging of metastasis in adult Zebrafish

Research article

Characteristics and outcome in patients with non-specific symptoms and signs of cancer referred to a fast track cancer patient pathway; a retrospective cohort study

Research article

Single-cell mRNA profiling reveals transcriptional heterogeneity among pancreatic circulating tumour cells

Research article

Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube

Research article

Metastatic polyp of the gallbladder from renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits